Login to Your Account

Argos between 'roca'-nd hard place as phase III mRCC trial halted for futility

By Marie Powers
News Editor

Wednesday, February 22, 2017

Jeff Abbey, president and CEO of Argos Therapeutics Inc., needed all of three minutes to deliver the news that Argos was stopping the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription